SAN DIEGO, CA -- (Marketwired) -- 03/04/14 --
NuVasive, Inc. (NASDAQ: NUVA), a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, is excited to announce its participation at the 30th Annual Meeting of the American Association of Neurological Surgeons (AANS) Congress of Neurological Surgeons (CNS) Joint Section on Disorders of the Spine and Peripheral Nerves from Wednesday, March 5th to Saturday, March 8th, in booth #106 at The Walt Disney World Swan and Dolphin Resort in Orlando, Fl.
With several thousand surgeons in attendance, the theme of this year's meeting is "putting patients first in an era of change and solutions for the future." NuVasive will demonstrate its comprehensive spine portfolio and offer two "what's new sessions."
"Every year, we look forward to partnering with the joint spine section (AANS/CNS) and participating in the annual meeting," said Pat Miles, President of Global Products and Services. "This year's theme directly aligns with NuVasive's commitment to truly transform the quality of patient lives with game-changing technology. Our commitment extends beyond our products and procedures to include patient education programs like The Better Way Back® and The NuVasive Spine Foundation™. Our innovative solutions and well-established patient education programs are an invaluable part of our commitment to further the quality and future of spine patient care."
NuVasive® is scheduled to participate in the following events at AANS/CNS:
- NuVasive Exhibit Booth #106: The NuVasive exhibit booth will feature a number of innovative, minimally disruptive products and procedures including: XLIF®, MAS® TLIF, MAS PLIF, PCM®, Bendini®, Precept®, NVM5®, and Biologics.
- NuVasive "What's New Sessions": NuVasive will host two 10 minute presentations in the exhibit hall-demo theater.
- Thursday, March 6th from 10:00 - 10:10 a.m. titled, "Medialized Minimally Disruptive PLIF," presented by David Jones, M.D.
- Friday, March 7th from 9:30 - 9:40 a.m. titled, "Computer Assisted Rod Bending," presented by Robert Isaacs, M.D.
- NuVasive will participate in two special courses in the Americas Seminar Room:
- Wednesday, March 7th from 1:30 - 5:30 p.m. titled, "Advanced MIS Techniques - Managing MIS Complications," led by course directors: Daniel J. Hoh, M.D. and Langston T. Holly, M.D.
- Friday, March 7th from 1:30 - 5:30 p.m. titled, "Hands on Spine: Indications, Techniques and Complication Avoidance for the NP/PA," led by course directors: Michael P. Steinmetz, M.D., Andrea L. Stayer, M.D., and Daniel J. Hoh, M.D.
Click here to download the complete AANS/CNS preliminary program.
The objectives of the American Association of Neurological Surgeons (AANS) / Congress of Neurological Surgeons (CNS), are to foster the use of spinal neurosurgical methods for the treatment of diseases of the spinal neural elements, the spine and peripheral nerves, to advance neurosurgery and related sciences, to improve patient care, to support meaningful basic and clinical research, to provide leadership in continuing education, and to promote administrative facilities necessary to achieve these goals.
NuVasive is an innovative global medical device company that is changing spine surgery with minimally disruptive surgical products and procedurally integrated solutions for the spine. The Company is the 4th largest player in the $8.7 billion global spine market.
NuVasive offers a comprehensive spine portfolio of more than 90 unique products developed to improve spine surgery and patient outcomes. The Company's principal procedural solution is its Maximum Access Surgery, or MAS® platform for lateral spine fusion. MAS provides safe, reproducible, and clinically proven outcomes, and is a highly differentiated solution with fully integrated neuromonitoring, customizable exposure, and a broad offering of application-specific implants and fixation devices designed to address a variety of pathologies.
Having pioneered the lateral approach to spine fusion, NuVasive continues to be at the forefront of the spine industry's shift toward less invasive solutions. The Company's dedication to innovation continues to spawn game changing technology such as the PCM® motion preserving disc for the cervical spine, XLIF® Corpectomy for tumor and trauma, and Armada®, which treats adult degenerative scoliosis in a less invasive fashion. The Company has also developed procedural solutions that completely redefine and improve upon traditional procedures like TLIF, PLIF, Posterior Fixation, and ALIF. NuVasive's solutions are increasingly being adopted internationally, as the Company lays the groundwork to continue growing as a global business and to offer industry-leading, Absolutely Responsive customer service to surgeons world-wide. NuVasive® is focused on becoming a $1 Billion Start-up™; taking market share by maintaining a commitment to Superior Clinical Outcomes, Speed of Innovation®, and Absolute Responsiveness®.
NuVasive cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's minimally disruptive surgical products by spine surgeons, development and acceptance of new products or product enhancements, expansion of our network of sales representatives, and the other risks and uncertainties described in NuVasive's press releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
Source: NuVasive, Inc.